P2-12-31: Moderate Immunohistochemical Expression of HER2 (2+) without HER2 Gene-Amplification Is a Negative Prognostic Factor in Early Breast Cancer
| Autor: | Furio Maggiorotto, Riccardo Ponzone, Cont N Tomasi, Massimo Aglietta, Filippo Montemurro, Ivana Sarotto, Stefania Redana, Valentina A. Rossi |
|---|---|
| Rok vydání: | 2011 |
| Předmět: |
Gynecology
Oncology Cancer Research medicine.medical_specialty Multivariate analysis biology business.industry Hazard ratio Cancer medicine.disease HercepTest Surgical pathology Trastuzumab Ki-67 Internal medicine biology.protein medicine Immunohistochemistry skin and connective tissue diseases business neoplasms medicine.drug |
| Zdroj: | Cancer Research. 71:P2-12 |
| ISSN: | 1538-7445 0008-5472 |
| Popis: | Purpose: We sought to evaluate whether moderate HER2 immunohistochemical (IHC) expression (2+ and no HER2/amplification) identifies early breast cancer (EBC) with a distinct prognostic profile. Methods: A total of 1295 women (median age 58, range 22–94) undergoing surgery for EBC from Jan 1995 to Sept 2009 were retrospectively reviewed. All patients had undergone HER2 testing by the HercepTest and, when needed, by fluorescence in-situ hybridization (FISH). All tests were carried on at our Institutional Surgical Pathology laboratory. The impact of HER2 status on disease-free survival (DFS) was corrected for other clinical and pathological potential covariates by Cox Proportional Regression Analysis. Results: A total of 494 (38%), 486 (38%), 119 (9%) and 196 (15%) of the patients had HER2 0+, 1+ 2+ and positive (3+ or FISH+) tumors, respectively. Sixty-one of 196 patients with HER2−positive EBC received adjuvant trastuzumab. A total of 298 DFS events occurred at median follow-up of 59 months (4-137 months). By using HER2 0+ status as reference, multivariate analysis revealed that HER2 2+ expression was associated with a significant increase in the risk of a DFS event (HR 2.303, 95% C.I. 1.501−3.533, p Conclusion: Moderate HER2 positivity (IHC 2+/FISH negative) identifies EBC patients at increased risk of a DFS event, regardless of hormone receptor status. Due to suggestions from large randomized trials that the benefits of trastuzumab may not be limited to HER2−positive tumors, patients with HER2 2+ EBC are ideal candidates for studies testing this hypothesis. Multivariate Hazard Ratios, corrected by age, lymph-node status, tumor diameter, tumor grade, proliferation (Ki 67 index) and receipt of adjuvant chemotherapy Citation Information: Cancer Res 2011;71(24 Suppl):Abstract nr P2-12-31. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|